Physician profile
Staley C Moore
NPI 1740236959
$3,654.06
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,797 · 2020: $1,267 · 2021: $590.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $541.67 | 2019-2021 | |
| Amgen INC. | $454.40 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $325.32 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $256.83 | 2019-2021 | |
| Glaxosmithkline, LLC. | $253.89 | 2019-2021 | |
| Amarin Pharma, INC. | $219.65 | 2019-2021 | |
| Pfizer INC. | $214.92 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.39 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.46 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $149.11 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $117.56 | 2019-2020 | |
| Lilly USA, LLC | $114.99 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $91.69 | 2019-2021 | |
| Eisai INC. | $89.26 | 2019-2021 | |
| Allergan, INC. | $61.94 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $55.59 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.46 | 2019 | |
| Ironwood Pharmaceuticals, INC | $46.55 | 2019-2021 | |
| Boston Scientific Corporation | $45.83 | 2019-2020 | |
| Abbvie INC. | $44.26 | 2020-2021 | |
| Daiichi Sankyo INC. | $43.69 | 2020-2021 | |
| Esperion Therapeutics, INC. | $32.63 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.22 | 2019 | |
| Abbott Laboratories | $16.00 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $15.95 | 2019 | |
| Philips North America LLC | $14.35 | 2020 | |
| Sunovion Pharmaceuticals INC. | $12.85 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.94 | 2021 | |
| Currax Pharmaceuticals LLC | $11.66 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Staley Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.